reports
CytoSorbents And Converge Biotech Announce Strategic Partnership to Ex...
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and , a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in ...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Resu...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 mill...
CytoSorbents Submits Health Canada Medical Device License Application ...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack patients requiring surgerySuccessful MDSAP certification confirms compliance with Health Canada and U.S. FDA quality management system requirements, replacing FDA audit and inspection if requiredHealth Canada and U.S. FDA regulatory decisions expected in 2025 PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a lea...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the U.S. Food and Drug Administration (FDA) has accepted its De Novo medical device application for DrugSorb™-ATR and ini...
CytoSorbents to Report Third Quarter 2024 Operating and Financial Resu...
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2024 operating and financial results after the market close on Thursday, November 7, 2024. CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Webcast Details:Date: Thursday, November 7, 2024Tim...
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to...
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update The De Novo medical device application for DrugSorb™-ATR is eligible for FDA priority review as an FDA Breakthrough Designated Device for this indicationThe Health Canada Medical Device License application is ready for submission, pending the expected receipt of Medical Device Single Audit Program (MDSAP) certification in the near futureExpecting FDA and Health Canada decisions in 2025 PRINCETO...
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Inve...
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New...
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 563...
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024 (the “Grant Date”) to its newly-hired Chief Financial Officer, Peter J. Mariani. The inducement equity awards consist of (i) a non-qualified stock option to purchase ...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Res...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by 10% and reduced operating loss by 48%Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestone PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reporte...
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer CytoSorbents CFO Kathleen P. Bloch Retires PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Res...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024. CytoSorbents’ management will host a live conference call, presentation webcast, and a question and answer session starting at 4:30PM EDT the same day. Webcast Details:Date: Tuesday, August 13, 2024Ti...
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requir...
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share. On July 26, 2024, CytoSorbents received notification from the Listing Qualifications Department of the Nasdaq Stock Marke...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Web...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website “Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned an...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Web...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website “Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned an...
CytoSorbents to Present at the Inaugural American Association of Physi...
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present at the 1st Annual , taking place on July 18-22, 2024 at the Mariott Marquis Hotel in New York, NY. This event will host over 3,000 physicians, healthcare professionals, and le...
CytoSorbents Secures $20 Million Credit Facility
CytoSorbents Secures $20 Million Credit Facility Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR in the U.S. and Canada PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 milli...
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most progressive healthcare systems in the world PRINCETON, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the regulatory approval of in Ta...
CytoSorbents Announces the Launch and Immediate Availability of the Pu...
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the European Union (E.U.) PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the launch...
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT. When: Thursday, June 6, 2024, at 10:00 ΑΜ EDTWebcast: Requirements: As described in the proxy materials previously distributed, stockholders as of the close of business on April 12, 2024, the recor...
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing C...
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal (STAR...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.